Immunotherapy combined with neoadjuvant chemotherapy is proving to be a promising approach in treating early hormone receptor-positive, HER2 negative breast cancer. Recent clinical studies have demonstrated that immune checkpoint inhibitors (ICIs) can significantly increase pathological complete response (pCR) rates in this patient population. Although these findings showcase the potential benefits of integrating immunotherapy into treatment regimens for early breast cancer, the emergence of immune-related adverse effects underscores the complexities associated with this therapeutic approach.
While immunotherapy has shown efficacy in triple-negative breast cancer, its application in hormone receptor-positive tumors has been challenging due to their lower immunogenicity. Trials combining ICIs with chemotherapy have exhibited enhanced tumor eradication prior to surgery, but the clinical relevance of these improved pCR rates necessitates validation through long-term survival data. Moreover, the heightened immune-related toxicities associated with this combination therapy emphasize the importance of cautious patient selection and vigilant monitoring throughout treatment.
Researchers are exploring innovative strategies to augment the efficacy of ICIs in hormone receptor-positive breast cancer. One such strategy involves the concurrent administration of radiation therapy and immunotherapy, with preliminary evidence suggesting a potential boost in antitumor immune responses. These combined approaches hold promise in overcoming resistance mechanisms that have historically hindered the effectiveness of immunotherapy in luminal-like breast cancers.
Experts emphasize the critical need for validated predictive biomarkers to identify patients who are most likely to benefit from immunotherapy, while also mitigating the risk of unnecessary toxicity in non-responders. As novel treatment combinations and schedules are optimized, precision medicine approaches will play a pivotal role in maximizing treatment outcomes. The evolving landscape of immunotherapy in the neoadjuvant setting may soon redefine the standard of care for early hormone receptor-positive, HER2 negative breast cancer, pending further validation from ongoing trials with extended follow-up periods.
Reference: Arecco L et al. Immunotherapy in the neoadjuvant treatment of hormone receptor-positive/HER2-negative early breast cancer: novel approaches and future perspectives. Curr Opin Oncol. 2025. doi:10.1097/CCO.0000000000001183
Key Takeaways:
– Immunotherapy combined with neoadjuvant chemotherapy shows promise in enhancing pathological complete response rates in early hormone receptor-positive, HER2 negative breast cancer.
– Careful patient selection and monitoring are crucial due to the increased risk of immune-related toxicities associated with this combination therapy.
– Novel strategies such as concurrent radiation therapy and immunotherapy are being explored to improve the effectiveness of immunotherapy in hormone receptor-positive breast cancer.
– The identification of predictive biomarkers and the implementation of precision medicine approaches are essential for optimizing patient outcomes with immunotherapy in early breast cancer.
Tags: immunotherapy
Read more on emjreviews.com